As seen in the article Planting the Seed for Speed, iBio’s biotherapeutics manufacturing facility (formerly Caliber Biotherapeutics) is moving forward with development of the drug iBio-DFB03 which treats systemic sclerosis, and has cleared the first hurdle for the development and manufacture of a protein to treat neonatal respiratory distress syndrome (RDS).
More information on EEA’s involvement in the design and construction of the facility can be found in our Caliber Biotherapeutics case study. EEA is also a member of the Klyo Collaborative whose mission is to solve lifecycle problems in the biopharmaceutical industry.
Categories: EEA Experience
